---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-26-000810"
form_type: "8-K"
ticker: "EDSA"
cik: "0001540159"
company_name: "Edesa Biotech, Inc."
filed_at: "2026-02-13T23:59:59+00:00"
generated_at: "2026-05-16T02:46:29.163260+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Edesa Biotech Q1 FY2026 net loss $2.2M; progresses EB06 vitiligo Phase 2 prep

## Summary
- Net loss of $2.2M ($0.28/share) vs. $1.6M ($0.48/share) a year ago; operating expenses $2.3M.
- Cash and equivalents $12.1M; working capital $12.0M at Dec 31, 2025.
- EB06 (anti-CXCL10) manufacturing underway for Phase 2 vitiligo study; patient enrollment targeted mid-2026.
- Paridiprubart Phase 3 ARDS data under subgroup analysis; plans to present at scientific conferences.
- Participating in GVFS, BIO Europe Spring, ATS 2026 and other conferences March-May 2026.

## SEC filing metadata
- accession: 0001171843-26-000810
- form_type: 8-K
- ticker: EDSA
- cik: 0001540159
- company_name: Edesa Biotech, Inc.
- filed_at: 2026-02-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1540159/000117184326000810/0001171843-26-000810-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1540159/000117184326000810/f8k_021226.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-26-000810
- JSON: https://secwatch.observer/filing/0001171843-26-000810.json
- Plain text: https://secwatch.observer/filing/0001171843-26-000810.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.